Moleculin Biotech
Yahoo Finance • 5 days ago
Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin
HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral i... Full story
Yahoo Finance • 11 days ago
Moleculin Biotech files to sell 64.86M shares of common stock by selling shareholder
* Moleculin Biotech (NASDAQ:MBRX [https://seekingalpha.com/symbol/MBRX]) filed to sell 64.86 million common stock. * This prospectus is not an offer to sell these securities. * The company will not receive any proceeds from the sale... Full story
Yahoo Finance • 21 days ago
Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial
European expansion in September across Georgia, Italy, Lithuania, Poland, Romania, Spain, and US 13 subjects recruited (treated, enrolled, or screened) Forecasts total recruitment of 20 or more subjects by end of September On track to r... Full story
Yahoo Finance • 22 days ago
Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia
Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for initial data unblinding HOUSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or th... Full story
Yahoo Finance • last month
Thursday's session: top gainers and losers
Looking for insights into the US markets one hour before the close of the markets on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] TOP GAINERS TICKER CHANGE... Full story
Yahoo Finance • last month
Let's take a look at the stocks that are in motion in today's session.
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session. [topmovers] TOP GAINERS TICKER CHANGE COMMENT SOGP [https://www.cha... Full story
Yahoo Finance • last month
The market is filled with gapping stocks in Thursday's session.
In today's session, there are notable price gaps in the US markets on Thursday. Take a closer look at the stocks that are gap up and gap down. [gap] GAP UP STOCKS TICKER CHANGE COMMENT SOGP [https://www.chartmill.com/stock/qu... Full story
Yahoo Finance • last month
Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds
HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses,... Full story
Yahoo Finance • last month
Moleculin Issues New Positive AML Overall Survival Data:
Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8) Median OS of 2nd Line efficacy evaluable population of 12 months (n=9) Median OS of Intent to Treat population (1L-7L) of 9 months (n=22) OS demonstrat... Full story
Yahoo Finance • 2 months ago
Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
– Live video webcast on Wednesday, August 20th at 2:00 PM ET HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio o... Full story
Yahoo Finance • 2 months ago
Moleculin Reports Second Quarter 2025 Financial Results and Highlights
- Continues recruitment and opens US and EU sites for the Phase 2B/3 MIRACLE trial - 20+ additional clinical sites in Europe and the US expected to begin recruitment by the end of Q3 - Anticipated data readout of MIRACLE Part A targete... Full story
Yahoo Finance • 2 months ago
Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment
Presented data highlights the potential of Annamycin for treating broad range of human cancers, including high-need oncology indications Annamycin currently in late-stage clinical development in combination with cytarabinefor the treatmen... Full story
Yahoo Finance • 2 months ago
Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin
– New patent enhances market position in Europe HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candid... Full story
Yahoo Finance • 2 months ago
What's going on in today's after hours session
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT RCON [https://www.chartmill.com/stock/quote/RCON/... Full story
Yahoo Finance • 2 months ago
What's going on in today's session
Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] TODAY'S TOP GAINERS TICKER CH... Full story
Yahoo Finance • 2 months ago
Moleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
– Video webcast now available on-demand HOUSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates tar... Full story
Yahoo Finance • 2 months ago
Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships
40+ year career at Roche founded on dedication to bringing new innovative medicines to patients and making them accessible HOUSTON, July 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”)... Full story
Yahoo Finance • 3 months ago
Moleculin Biotech enters $6.5 million at-the-market equity offering agreement
Moleculin Biotech, Inc. (NASDAQ:MBRX), a biotechnology company with a current market capitalization of $13.42 million, announced Friday that it has entered into an At The Market Offering Agreement with Roth Capital Partners, LLC. Under the... Full story
Yahoo Finance • 3 months ago
Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans
Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 MIRACLE trial Recent EU approval from the European Medicines Agency (EMA) boosts trial profile Enrollment in Part A o... Full story
Yahoo Finance • 3 months ago
Moleculin Biotech prices 16.08M shares at 37c in public offering
Moleculin Biotech (MBRX) announced the pricing of a public offering consisting of 16,080,000 shares of common stock and Series E warrants to purchase up to 48,240,000 shares of its common stock, at a combined public offering price per shar... Full story
